AstraZeneca Beats Q2 Earnings Forecasts With Oncology and Rare Disease Growth

AZN delivered a Q2 2026 earnings beat driven by its oncology and rare disease franchises, reporting core earnings per share of $2.63, up about 18% at constant currency and ahead of the roughly $2.48 analysts expected. Total revenue rose about 5% to roughly $15.38 billion, landing fractionally below the consensus figure near $15.39 billion, so the quarter was a profit beat paired with a marginal top-line miss.

The composition is what carried the result. Cancer drug sales grew roughly 15% and rare disease revenue rose about 8%, both comfortably ahead of the group average, which means the therapeutic areas AstraZeneca has spent most heavily on are the ones now doing the compounding. That mix shift also supports margins, because these franchises generally carry more favourable economics than the older primary-care portfolio they are gradually replacing in the revenue base.

Management left its outlook unchanged, guiding to low double-digit percentage growth in core EPS at constant currency for full-year 2026 alongside mid-to-high single-digit total revenue growth, and reaffirmed the $80 billion annual revenue ambition it has set for 2030. Holding guidance after a revenue line that came in slightly light suggests confidence in second-half phasing rather than a reset.

For investors the questions ahead are whether oncology momentum can be sustained as newer entrants reach the market, how durable the rare disease contribution proves, and what currency does to reported figures given how much of the growth is flattered on a constant-currency basis. Pricing and reimbursement policy remains the sector-wide variable that could alter the path to the 2030 target.

Related Stocks

• AZN